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Abstract
Endothelial dysfunction is considered to be an early event in atherosclerosis and plays a
pivotal role in the development, progression and clinical complications of atherosclerosis.
Previous studies have shown the beneficial effects of combined inhibition of thromboxane
synthase and antagonism of thromboxane receptors by BM-573 on atherosclerosis; how-
ever our knowledge about the beneficial effects of BM-573 on endothelial function and
increased blood pressure related to early stage of atherosclerosis is limited. In the present
study, we investigated the effects of short-term (3μM, 1 hour) and chronic (10mg/L, 8
weeks) treatments with BM-573 on vasodilatory function, nitric oxide (NO) bioavailability,
oxidative stress and systolic blood pressure in 15 weeks old apolipoprotein E-deficient
(ApoE-KO) mice. ApoE-KOmice showed a reduced endothelium-derived relaxation. In
addition, NO bioavailability was reduced and oxidative stress and blood pressure were
increased in ApoE-KO mice versus wild-type mice. BM-573 treatments were able to
improve the relaxation profile in ApoE-KO mice. Short-term effects of BM-573 were mainly
mediated by an increased phosphorylation of both eNOS and Akt, whereas BM-573 in vivo
treatment also reduced oxidative stress and restored NO bioavailability. In addition, chronic
administration of BM-573 reduced systolic blood pressure in ApoE-KOmice. In conclusion,
pharmacological modulation of TxA2 biosynthesis and biological activities by dual TP
antagonism/TxAS inhibition with BM-573, already known to prevent plaque formation, has
the potential to correct vasodilatory dysfunction at the early stages of atherosclerosis.
Introduction
Numerous studies have emphasized the pivotal role of endothelial dysfunction in the develop-
ment, progression or clinical complications of atherosclerosis [1, 2]. Endothelial dysfunction
results from an unbalance between production and release of endothelial relaxing (NO, EDH
(F), PGI2) and contracting factors (ET-1, TxA2 and PGs). Although the endothelium plays
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multiple functions, a reduced vasodilatory response to pharmacological stimulation constitutes
a recognized indicator of endothelial dysfunction. Evidence of vasodilatory dysfunction has
been clearly documented in plaque-prone vessels of human or in animal models of dyslipide-
mia [3], although it remains to be characterized in the resistance vasculature.
The formation of prostacyclin (PGI2), thromboxane (TxA2), and isoprostanes is markedly
enhanced in patients with atherosclerosis [4, 5]. Activation of TxA2 receptors (TP receptors)
causes potent vasoconstriction and induces increased formation of superoxide anions (O2
-)
and peroxynitrite (ONOO-), a product of rapid reaction of O2
- with nitric oxide (NO) that
accelerates NO degradation and reduces its availability [6, 7]. In the last decades, numerous
reports have suggested that TP receptor antagonism (with sulotroban or terutroban) or direct
inhibition of thromboxane synthase (TxAS) (with furegrelate) can not only have antiplatelet
effects but also impact endothelial dysfunction as well as the inflammatory component of ath-
erosclerosis [8–11]. Failure to inhibit deleterious isoprostanes synthesis (known markers of
oxidative stress and TP receptor agonists) explains why the latter drugs did not live up to the
expectations in clinical trials. Therapeutic interest has thus switched to compounds that com-
bine thromboxane synthase inhibition and TP receptor antagonism, such as BM-573. In previ-
ous in vitro and ex vivo studies, BM-573 has been demonstrated as a potent dual compound
able to reduce TxA2 production by TxAS inhibition and to prevent the action of TxA2 by
blocking the TP receptors [12, 13]. In addition to its antiplatelet and antithrombotic effects,
BM-573 has proven to be effective in different animal models of cardiovascular diseases where
levels of TxA2 are increased [14, 15].
The principal aim of this study was to evaluate the impact of dual TxAS inhibition/TP
receptor antagonism by BM-573 on the endothelial dysfunction associated with hyperlipidemia
by focusing on the eNOS/NO pathway. To decipher the beneficial properties of BM-573, we
dissociated acute effects, associated to potential modulation of protein activity, from chronic
effects, potentially linked to protein expression. Effects of BM-573 were measured on endothe-
lial vasodilatory function, NO bioavailability, oxidative stress in resistance vessels from apoli-
poprotein E-deficient (ApoE-KO) mice at early stages of atherosclerosis. In this report, we
demonstrate that both acute and chronic BM-573 treatments improve the endothelial depen-
dent relaxation and prevent the increase of systolic blood pressure in ApoE-KO mice at early
stages of atherosclerosis.
Materials and Methods
Animals and Experimental protocols
ApoE-KO male mice and their wild-type littermates (C57BL/6J or WT), were obtained from
Charles River Laboratories (Belgium) and housed in a temperature controlled room with a
12:12 light-dark cycle and food and water ad libitum. After two weeks of acclimatization,
experimental procedures were performed. For vascular reactivity studies and sample collection
(aortae and blood), mice were euthanized by exsanguination under general anesthesia (Keta-
mine/Xylasine, 84 and 5mg/kg IP respectively). Telemetry catheters were implanted under gen-
eral anesthesia (Ketamine/Xylasine, 84 and 5mg/kg IP respectively) and mice were given
buprenorphine (0.1mg/kg SQ BID) during 5 days for analgesia.
To evaluate the acute effects of BM-573, mice (N = 8–12) were sacrificed at 15 weeks of age
and their isolated vessels were incubated in absence or presence of BM-573 3μM for 1 hour in
physiological salt solution buffer at 37°C. For chronic treatment, 7-weeks-old mice were ran-
domized into two groups (N = 8–12 animals in each group) to receive either vehicle or BM-573
(10mg/L) per os for 8 weeks. The doses used were based on previously published studies [14,
15]. All experimental procedures and protocols were approved by the local Ethics Committee
Effects of BM-573 at Early Stages of Atherosclerosis
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Vascular reactivity studies
Mice were sacrificed and second branch mesenteric arteries were mounted on a pressure myo-
graph as previously described [16]. Briefly, isolated micro-vessels (140–160μm) from Apo
E-KO andWT mice treated or not with BM-573 were dissected under a stereoscopic micro-
scope and mounted on a 110P pressure myograph (Ionoptix). Vessels were left to recover for
45–60 min in no-flow conditions (40mmHg, 37°C) in calcium-containing physiological salt
solution buffer (PSS). Acute effects of BM-573 were measured in vessels isolated from control
mice, exposed for 1h to BM-573 3μM (also named ex vivo or short-term treatment) while
chronic effects were evaluated in vessels from mice treated for 8 weeks with BM573 10mg/L. In
that case, the drug was excluded from all bathing solutions during the experimental procedure.
Changes in the outer diameters were tracked and measured with the Myoview software.
Nitric oxide availability assayed by electron paramagnetic resonance
spectroscopy in vivo and in situ
At the end of the treatment, NO bioavailability was assayed by Electron Paramagnetic Reso-
nance (EPR) spectroscopy in venous blood and isolated aortae from mice, as described previ-
ously [17]. Briefly, endothelial nitric oxide synthase (eNOS) activity was measured in isolated
aortic rings by EPR spin trapping as concentration of paramagnetic NO adduct accumulated in
tissue after stimulation by Ca(II) ionophore (ionomycin, 2μmol/L) at 37°C during 30 minutes
in presence of spin trap (colloid form of [Fe(II)-(DETC)2], 0.5mmol/L in KREBS buffer), and
was normalized by weight of dry aortae. The level of ferrous nitrosylated hemoglobin (Hb-NO)
circulating in whole blood, was quantified from the EPR signal of 5-coordinate-α-Hb-NO
using a hyperfine component of the spectrum (near g = 2.02) after subtraction of the EPR sig-
nal from protein-centered free radicals which overlapped with Hb-NO EPR signal. The EPR
spectra were recorded by a Bruker EMX100 spectrometer (X-band, microwave frequency
9.35GHz, modulation frequency, 100kHz) with the following setting: microwave power (MP),
20mW; modulation amplitude (MA), 0.5mT; 10 scans, at 77K using finger dewar.
Assessment of vascular ROS
Dihydroethidium (DHE), a sensitive superoxide anions (O2
-) probe, was used to evaluate in
situ production of vascular reactive oxygen species (ROS) in aortic tissues as described previ-
ously [18].
Quantitatively, basal SOD-sensitive ROS production was detected by EPR in isolated aortic
rings using a spin probe in situ. Briefly, aortic rings were preincubated in KREBS-DTPA-Hepes
buffer (0.1 mM DTPA, 20 mMHEPES, pH 7.5) in the presence or not of SOD (100 U/mL),
inserted in capillaries (Blaubrand1; 50 μl) immediately after addition of the ROS-sensitive
spin probe (1-Hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine, CM-H, Alexis Bio-
chemical Inc.) as described previously [19]. Specific methodological details are provided in the
S1 File. The kinetics of the CM EPR signal formation was recorded on-line in capillary inter-
posed into the cavity of the EPR spectrometer (MS400, Magnettech, X-band; microwave fre-
quency 9.35GHz, modulation frequency, 100kHz) with following setting: MP, 20mW; MA,
0.1mT; 10 scans during 10 minutes at 37°C. The rate of the CM radical formation was calcu-
lated using Magnettech kinetic software as a slope of linearized kinetic curve, obtained from
automatical recording of the signal, and normalized by the length of aortic rings.
Effects of BM-573 at Early Stages of Atherosclerosis
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Immunoblotting Experiments
At the end of the treatment, aortae were collected to evaluate Akt and eNOS phosphorylation
by Western blotting, as previously described [16, 20]. Western blotting was also used to assess
COX-2 protein expression in aorta homogenates. Specific methodological details are provided
in the S1 File.
Quantitative real-time PCR
Reverse transcription was done from total RNA using the SuperScript II RNase H− reverse
transcriptase and random hexamer primers (Invitrogen). Quantitative real-time PCR (qPCR)
analyses were done in triplicate using iQ SYBR Green Supermix (Bio-Rad). PCR fluorescence
data were obtained and analyzed with the IQ5 instrument (Bio-Rad). Specific methodological
details are provided in the S1 File.
Analysis of blood pressure and heart rate by implanted telemetry
Systolic blood pressure (SBP) signal and heart rate (HR) were measured in conscious, unre-
strained animals with surgically implanted, miniaturized telemetry devices (Datascience Corp.,
USA) as already described[17, 21]. Specific methodological details are provided in the S1 File.
Statistical analysis
Relaxation to ACh were expressed as a percentage of the level of preconstriction induced by
phenylephrine or KCl. For each concentration-response curve the maximum effect (Emax) was
calculated using non-linear regression analysis (GraphPad Prism Software, San Diego, CA). All
data are expressed as means ± SEM of experiments, with 'N' being the number of individual
mice used in each experiment. Statistical analysis was done by comparing the curve obtained in
resistance arteries treated with BM-573 with the control curve by means of a non-repeated
measure analysis of variance (ANOVA) followed by Bonferroni post-hoc test. For NO produc-
tion, oxidative stress, immunoblotting and qPCR experiments, the statistical analysis was done
using one-way ANOVA followed by Newman-Keuls post hoc test. For assessing the effect of
different treatments (BM-573 or vehicle) on blood pressure experiments, the statistical analysis
was done using two-way ANOVA followed by Bonferroni post-hoc test.
Results
Endothelial dysfunction in ApoE-KOmice microarteries
A reduced acetylcholine (ACh)-evoked relaxation illustrates that resistance mesenteric arteries
isolated from ApoE-KO mice showed an altered vasodilatory profile as compared to C57BL/6J
mice (Fig 1A). To analyse this dysfunction and the effects of ApoE-KO genotype on the endo-
thelium-dependent components of the relaxation, namely NO- and EDH(F)-mediated relaxa-
tion, experiments were performed in the presence or the absence of eNOS (L-O-NoArg) and
cyclooxygenase (COX) (indomethacin) inhibitors as well as in conditions where endothelium-
derived hyperpolarization was prevented (KCl 50mM). We showed that both the NO and EDH
(F) portions of the relaxation to ACh were reduced in isolated vessels of ApoE-KO mice (Fig
1B and 1C). On the contrary, we observed that in response to ACh 10μM, the NO/EDH(F)-
independent relaxation (assimilated to the COX-dependent relaxation) was significantly larger
in mesenteric arteries from ApoE-KOmice than in wild type (WT) mice (18.3 ± 3.6% in
ApoE-KO versus 9.0 ±4.2% in C57BL/6J; n = 4, P<0.05, Fig 1D). Additionally, preincubation
with the COX inhibitor, indomethacin, significantly improved the acetylcholine-mediated
maximal relaxation in ApoE-KO mice (Fig 1A), being without effect in isolated vessels from
Effects of BM-573 at Early Stages of Atherosclerosis
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C57BL/6J mice. Altogether these results suggest that arachidonic acid-derived factors partici-
pate in the vasodilatory dysfunction observed in resistance arteries of ApoE-KO mice. Note-
worthy, contraction levels were similar in all vessels independently of their origin (S1 Fig).
Effects of BM-573 on ApoE-KO vasodilatory dysfunction
Effects of short-term treatment with BM-573 were evaluated in resistance mesenteric arteries
exposed to BM-573 (3μM) for 1h versus controls. The BM-573- treatment improved the
Fig 1. Characterization of endothelial dysfunction in ApoE-KOmice. (A) Acetylcholine (ACh) evoked relaxation in second branch of mesenteric arteries
isolated from C57BL/6J and ApoE-KOmice after phenylephrine (Phe) contraction (10μM) in presence (filled) or absence (open) of indomethacin (10μM).
Isolated relaxation pathways: (B) NO-mediated relaxation was evaluated in presence of indomethacin (10μM) after contraction with high-KCl solution
(50mM). (C) EDH(F)-mediated relaxation was evaluated in presence of L-Ω-NoArg (100μM) and indomethacin (10μM) after contraction with phenylephrine
(10μM). (D) PGI2-dependent relaxation was performed in presence of L-Ω-NoArg (100μM) after KCl (50mM) contraction. Results are expressed as
mean ± SEM (N = 5–8 animals in each group). * P<0.05, ** P<0.01, *** P<0.001 ApoE-KO versus C57BL/6J mice, and # P<0.05 ApoE-KO (-Indo) versus
ApoE-KO (+Indo)
doi:10.1371/journal.pone.0152579.g001
Effects of BM-573 at Early Stages of Atherosclerosis
PLOS ONE | DOI:10.1371/journal.pone.0152579 March 28, 2016 5 / 17
relaxation evoked by ACh in resistance arteries of ApoE-KO mice (Fig 2A) with a significant
increase in both EDH(F) and NO components (Fig 2B and 2C). Whereas in microarteries of
C57BL/6J mice, BM-573 acute treatment did not affect the ACh relaxing responses (see Fig 2A,
2B and 2C). As expected, in the presence of indomethacin, no effect of BM-573 could be mea-
sured on ACh relaxation in ApoE-KO mesenteric arteries (data not shown).
Fig 2. Effects of short ex-vivo and long in-vivo BM-573 treatment on the microvascular relaxation. (A, B and C) relaxation experiments were performed
in microarteries isolated from 15-week-old mice preincubated in presence or absence of 3μMBM-573 during 1H (ex-vivo). (D, E and F) relaxation
experiments were done in vessels isolated from 15-week-old mice that have been treated or not with BM-573 (10mg/L of drinking water) during 8 weeks.
Acetylcholine-evoked relaxation was evaluated after phenylephrine or high-KCl solution (50mM) contraction to characterize: (A, D) Total-, (B, E) NO- or (C, F)
EDH(F)-mediated relaxations in second branch of mesenteric arteries isolated from C57BL/6J and ApoE-KOmice treated or not with BM-573. Results are
expressed as mean ± SEM (N = 5–8 animals in each group).* P<0.05, ** P<0.01 ApoE-KO versus C57BL/6J mice, and # P<0.05, ## P<0.01 ApoE-KO
versus ApoE-KO+BM-573 treatment.
doi:10.1371/journal.pone.0152579.g002
Effects of BM-573 at Early Stages of Atherosclerosis
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Effects of long-term treatment with BM-573 were measured in mesenteric microarteries iso-
lated from mice treated with 10mg/L BM-573 per os from week 7 to week 15. Noteworthy, in
order to characterize the chronic effects of BM-573 (in opposition to the acute responses mea-
sured in the short-term protocols), BM-573 was excluded from all bathing solutions during the
experimental procedure. We observed that the total endothelium-dependent relaxation was
increased in resistance arteries of ApoE-KO mice after in vivo treatment with BM-573 (Fig
2D). To specifically assess the effect of chronic BM-573 treatment on the NO component of
the relaxation, vessels were incubated with indomethacin and preconstricted with a high KCl
solution. In these conditions, a significant improvement of the ACh-evoked relaxation was
observed in resistance mesenteric arteries collected from BM573-treated ApoE-KO mice (Fig
2E). In conditions where vessels were incubated with NOS and COX inhibitors and precon-
stricted with phenylephrine (Phe), the relaxation to ACh of microarteries isolated from BM-
573-treated ApoE-KO mice remained significantly altered (vs control mice vessels) (Fig 2F),
suggesting that the EDH(F) component of the relaxation is not involved in the beneficial effects
of in vivo BM-573 treatment. Again, contraction levels were similar in all vessels independently
of their origin or treatment (S1 Fig).
Effects of BM-573 on NO production
NO production was measured by EPR in isolated aortae fromWT and ApoE-KOmice treated
or not with BM-573. Ionomycin-stimulated NO production was significantly depressed in aor-
tae coming from ApoE-KO mice (Fig 3A). While chronic BM-573 treatment did not influence
the extent of stimulated NO production, short-term BM-573 treatment improved the NO-pro-
duction in aortae of ApoE-KO mice, without influence on NO release in C57BL/6J aortae (Fig
3A). Circulating NO bioavailability, assessed by EPR as the level of nitrosylated hemoglobin
(Hb-NO) in whole venous blood, was also reduced in ApoE-KO mice (Fig 3B and 3C). Inter-
estingly, chronic treatment with BM-573 evoked a significant (P<0.05) increase in blood Hb-
NO levels both in WT and ApoE-KO mice (Fig 3C).
In order to evaluate the effects of BM-573 on eNOS signaling pathway, we measured the lev-
els of eNOS and Akt phosphorylation (Ser1177 and Ser473 respectively) in WT and ApoE-KO
mice aortae. Both p-Akt/Akt and p-eNOS/eNOS ratios were significantly reduced in vessels
from ApoE-KO mice versus WT mice (Fig 3D and 3E). Short-term treatment with BM-573
induced a significant increase in both eNOS and Akt phosphorylation in ApoE-KO vessels,
while chronical in vivo treatment with BM-573 cause a small but significant (P<0.05) increase
in eNOS phosphorylation in aortae of ApoE-KO mice (Fig 3D and 3E).
Effects of BM-573 on oxidative stress
Oxidative stress was evaluated in aortic samples using dihydroethidium (DHE) staining (Fig
4). Aortic rings from ApoE-KO mice presented a significant increase in DHE/DAPI ratio, indi-
cating an increased O2
- production (Fig 4A and 4B). While acute BM-573 treatment failed to
modify the DHE-positive signal, long-term treatment reduced the increased DHE staining in
aortic rings of ApoE-KO mice to a similar extent as that observed in aortae fromWTmice (Fig
4A and 4B). These results were supported by direct measurements of O2
- using in situ EPR in
isolated aortic rings fromWT and Apo-E KO mice (Fig 4C). We also confirmed that in vivo
BM-573 administration was able to prevent the increased O2
- production observed in
ApoE-KO mice (Fig 4C).
To evaluate the effects of BM-573 on the main sources of ROS in vascular tissues from
ApoE-KO mice, namely uncoupled eNOS and NADPH oxidase [22–24], eNOS monomer/
dimer ratio (as a marker of eNOS uncoupling) and NOX mRNA levels were quantitated in
Effects of BM-573 at Early Stages of Atherosclerosis
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Fig 3. Effects of BM-573 on NO availability and eNOS-derived production pathway. (A) Ionomycin (2μM) stimulated NO production was measured by
EPR spin trapping in isolated aortic rings from ApoE-KO and C57BL/6J mice treated or not with BM-573. The EPR signals of accumulated [Fe(II)NO-
(DETC)2] complex were normalized to dry tissue weight (N = 4–6 animals in each group). (B, C) NO bioavailability was measured as level of Hb-NO complex
assayed by EPR spectroscopy in venous blood: (B) typical EPR spectra of Hb-NO, presented as high-field component of the signal (hfs) after subtraction of
protein-centered free radical signal; (C) quantitation of Hb-NO in whole blood of ApoE-KOmice treated or not with BM573 (N = 6–12 animals in each group).
(D, E) Phosphorylation of Akt (Ser 473) and eNOS (Ser1177) measured by western blot in aorta homogenates. Results are expressed as mean ± SEM (N = 8
animals in each group). * P<0.05 ApoE-KO versus C57BL/6J mice, δ P<0.05 C57BL/6J versus C57BL/6J+BM-573 treatment and # P<0.05 ApoE-KO versus
ApoE-KO+BM-573 treatment.
doi:10.1371/journal.pone.0152579.g003
Effects of BM-573 at Early Stages of Atherosclerosis
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Fig 4. Effects of BM-573 on superoxide anions (O2
-) production. (A) Dihydroethidium (DHE) (right) and nuclear DAPI (left) staining in mice aortae. (B)
Values of red ethidium fluorescence normalized to blue DAPI fluorescence. (C) Basal O2
- production, assayed by EPR spectroscopy using CM-H spin probe.
Results are expressed as mean ± S.E.M. of four different sections obtained from each aortic ring (N = 8–12 animals in each group). * P<0.05 ApoE-KO
versus C57BL/6J mice and # P<0.05 ApoE-KO versus ApoE-KO+BM-573 treatment.
doi:10.1371/journal.pone.0152579.g004
Effects of BM-573 at Early Stages of Atherosclerosis
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mice thoracic aortae. While we were not able to document eNOS monomer/dimer ratio from
isolated vessels homogenates by Western blotting for technical reasons, NOX-2 and NOX-4
mRNA were increased in Apo-E KO mice compared to WT mice (Fig 5A and 5B), and NOX-1
mRNA levels were similar in tissues from all experimental groups (data not shown). BM-573
Fig 5. Effects of BM-573 on NOX-2, NOX-4 and COX-2 expression.Quantitative real-time PCR-based analysis of NOX-2 (A), NOX-4 (B) and COX-2 (C)
expression in aortic homogenates from C57BL/6J and ApoE-KOmice treated or not with BM-573. (D) COX-2 protein expression assessed by western
blotting. Results are expressed as mean ± SEM (N = 3–6 animals in each group). * P<0.05 ApoE-KO versus C57BL/6J mice and # P<0.05 ApoE-KO versus
ApoE-KO+BM-573 treatment.
doi:10.1371/journal.pone.0152579.g005
Effects of BM-573 at Early Stages of Atherosclerosis
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in vivo treatment however failed to influence either NOX-2 or NOX-4 up-regulation (Fig 5A
and 5B).
Effects of BM-573 on COX-1 and COX-2 isoforms expression
In resistance vessels from ApoE-KOmice, we observed an up-regulation of COX-dependent
tone modulation (see Fig 1) as illustrated by an improved PGI2-associated relaxation. This was
counter-balanced by an even more severe COX-dependent inhibition of NO/EDH(F) vasodila-
tion. In agreement, the expressions of COX-2 mRNA and protein were higher in 15-weeks-old
ApoE-KO mice than in WTmice. After 8 weeks of BM-573 in vivo treatment, vascular COX-2
mRNA expression was downregulated in ApoE-KO mice to a similar extent as that observed in
WTmice (Fig 5C). These results were confirmed at the protein level by Western blotting (Fig
5D). In contrast, the expression of COX-1 mRNA was unmodified among the experimental
groups (S2 Fig).
Effects of BM-573 on increased blood pressure in ApoE-KOmice
BM-573 treatment significantly reduced the increase in systolic blood pressure (SBP) and, con-
versely, increased the reduced heart rate (HR) observed in ApoE-KO mice (Fig 6).
Discussion
The present study was designed to evaluate the beneficial effects of BM-573, a dual TxAS inhib-
itor and TP receptor antagonist, on the vasodilatory function and blood pressure in ApoE-KO
mice at early stage of atherosclerosis. First, our results showed that resistance microarteries
from ApoE-KO mice present an impairment of the vasodilatory response independently of the
onset of plaque formation. This dysfunction arises from a defect in both NO- and EDH(F)-
mediated vasodilation combined to an altered prostanoid balance. Second, we demonstrated
that the inhibition of the TxA2 pathway by BM-573 prevent the altered relaxing response
observed in the vasculature from ApoE-KO mice, through the restoration of NO bioavailabil-
ity. In addition, in vivo telemetry documented the normalization of systolic blood pressure in
Fig 6. Effects of BM-573 on systolic blood pressure (SBP) and heart rate (HR). Effects of long-term BM-
573 administration on systolic blood pressure (SBP) (A) and heart rate (HR) (B) measured by telemetry in
ApoE-KOmice. Values are expressed as mean ± SEM (N = 4–6 animals in each group). # P<0.05, ## P<0.01
and ### P<0.001 ApoE-KO versus ApoE-KO+BM-573 treatment.
doi:10.1371/journal.pone.0152579.g006
Effects of BM-573 at Early Stages of Atherosclerosis
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BM-573-treated ApoE-KO mice. Although the underlying mechanisms seem to be different for
short- and long-term BM-573 administration, a potentially additive mechanism could account
for the beneficial effects of BM-573 in ApoE-KO mice at early stage of atherosclerosis.
ApoE-KO mice develop severe hypercholesterolemia and atherosclerotic lesions mimicking
atherogenesis in humans. In addition, endothelial dysfunction and an elevated production of
numerous arachidonic acid-derived mediators including TxA2 and prostaglandins have been
described [25]. Although previous works have shown an impaired ACh response in ApoE-KO
arteries, these studies were performed in older ApoE-KO mice (> 20 weeks) fed with high-fat
diet to accelerate vascular atherosclerotic lesions formation. In these animals, endothelial dys-
function was evidenced only in plaque-prone vessels such as aorta or carotid artery [26, 27].
Interestingly, our results demonstrate an altered relaxation in response to ACh in resistance
mesenteric vessels from young ApoE-KO mice under regular diet, where structural vascular
changes and atherosclerotic lesions have not yet developed [28, 29]. This observation empha-
sizes the role of vasodilatory dysfunction as an early marker of atherosclerosis and a contribu-
tor to its pathogenesis. We found that the two major endothelium-dependent relaxing
pathways, namely nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDH
(F)), are altered in the vasculature of these young ApoE-KO mice. A reduced NO-dependent
vasodilation is in line with early reports of endothelial dysfunction in resistance vessels from
hypercholesterolemic patients [30]. The role of EDH(F) in pathologic vessels is more contro-
versial considering that some reports mention a minimal alteration while others described an
enhanced endothelium-dependent hyperpolarization and dilation in response to ACh.
Whether the stage of atherosclerotic disease could account for these discrepancies requires fur-
ther investigation.
Increased TxA2 production and TP receptor activation induce an impairment of endothe-
lium-dependent relaxation and increase of reactive oxygen species [6, 7]. Previous studies have
also shown that independently, TP receptor antagonists and TxAS inhibitors were able to
improve endothelial function in different vascular diseases [31–33]. BM-573, a potent dual
TxAS inhibitor and TP receptor antagonist [12], has shown to inhibit the development of vas-
cular atherosclerotic lesions in different animal models of atherosclerosis [14, 15]. Specifically
in ApoE-KOmice, BM-573, but not ASA, significantly decreased atherosclerotic lesions forma-
tion, showing that a dual TxAS inhibition and TP receptor antagonism is more effective in
delaying atherosclerosis than single inhibition of TxA2 formation. Such benefit could be attrib-
uted to the antagonism of BM-573 on TP receptors, and the inhibition of deleterious effects
from COX-independent such as isoprostanes. The current study now identifies the restoration
of the eNOS/NO pathway as a major mechanism supporting the effects of dual inhibition of
TxAS and TP receptor blockade in ApoE-KO mice at early stage of atherosclerosis. Whether
this dual inhibition is superior to pure TP receptor antagonism is still unknown. Based on pre-
vious studies, we could speculate that blocking TxA2 synthesis might promote the accumula-
tion of prostaglandin H2, and the synthesis of vasculoprotective prostanoids such as PGI2, due
to BM-573 reduced TxA2 but fully preserved prostacyclin biosynthesis [12–14]. However, this
was not evaluated in our study.
Among the underlying mechanisms of reduced NO availability in atherosclerosis, both the
impaired enzymatic activity of eNOS and the accelerated degradation of NO by O2
- are pro-
posed to play central roles [34–36]. Here, we showed that stimulated NO production and avail-
ability were significantly depressed and Akt-eNOS pathway altered in aortic rings from
ApoE-KO mice. Furthermore, it has been described that TP receptor activation impairs endo-
thelial NO-dependent vasorelaxation through the inhibition of both basal and stimulated Akt
and eNOS phosphorylation via a Rho kinase-dependent mechanism [37, 38]. In our study,
short exposure to BM-573 improved ACh relaxation and stimulated NO-production in
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ApoE-KO arteries together with an increased phosphorylation of both Akt and eNOS. Surpris-
ingly, acute treatment with BM-573 also increased both Akt and eNOS phosphorylation in WT
mice. This effect in WTmice could be due to blockade of TP receptor, which might protect
basal phosphorylation of Akt in endothelial cells and in turn improve eNOS phosphorylation.
Moreover, our data also indicate that in the long-term, BM-573 can restore NO availability in
ApoE-KO mice through oxidative stress reduction. BM-573 chronic treatment reduced O2
-
production in aortic rings from ApoE-KOmice and enhanced circulating NO levels in both
WT and ApoE-KO mice, strongly suggesting that the observed increase in NO availability is
associated with reduced NO degradation. Consistently, a rise in O2
- production has been dem-
onstrated to accelerate NO degradation in both human and animal atherosclerotic vessels [39,
40]. Numerous oxidase systems might contribute to enhanced ROS levels in the vasculature,
notably a PKC-dependent activation of NADPH oxidase. Here, we found a consistent up-regu-
lation of NOX-2 and NOX-4 in aortae of ApoE-KO mice. However, BM-573 chronic treatment
did not prevent NOX upregulation. Additionally, activation of COXs is also a source of O2
- due
to the COX-dependent production of arachidonic acid-derived mediators, such as TxA2 and
8-isoprostanes, which activate TP receptors and may contribute to the development of endo-
thelial dysfunction in both human and animal models of atherosclerosis [41–44]. In the present
study, we found that COX-2 mRNA and protein expressions were increased in ApoE-KO mice
and that BM-573 chronic treatment was able to prevent this rise. This is further supported by
the greater COX-related modulation of tone observed in ApoE-KO mice (see Fig 1A and 1D).
Although our results are in apparent contradiction with data obtained with another dual TP
receptor antagonist and TxAS inhibitor on human umbilical vein endothelial cells [45], we can-
not exclude that a modulation of COX2 expression in smooth muscle cells could explain our
results as they were obtained from whole vessels homogenates. Moreover long-term treatment
with BM-573 was also associated with a significantly enhanced p-eNOS/eNOS ratio. This, how-
ever, might reflect a different reality than that observed after short-term exposure to BM-573
and could account for a moderate phosphorylation of larger amounts of coupled eNOS. For
technical reasons, we failed to document eNOS uncoupling as previously reported by others in
a TxAS-dependent model [7]. Reduced oxidative stress by BM-573 and abrogation of the
vicious circle that lead to eNOS uncoupling could however not be discarded, specifically for the
BM-573 chronic treatment. An increased proportion of coupled eNOS, that is only moderately
activated through phosphorylation would translate in an increased p-eNOS/eNOS ratio in
denaturing conditions, an insignificant ionomycin-stimulated NO production in isolated ves-
sels and would generate a mild but significant increase in circulating NO in chronically BM-
573 treated mice.
Finally, we evaluated whether treatment with BM-573 could prevent the progression of
hypertension observed in ApoE-KO mice. Although a controversy remains concerning the
development of hypertension in ApoE-KO mice [21, 46, 47], we analyzed the effects of BM-
573 on blood pressure in young ApoE-KO mice through direct arterial pressure measurements
by telemetric recordings. In agreement with our previous results, ApoE-KO mice presented a
significant and time-dependent increase of systolic blood pressure concomitant to a slight
decrease of heart rate. Consistently with the improved vasodilatory profile afforded by both
acute and chronic BM-573 treatments on the NO pathway, we showed that BM-573 was able
to restore systolic blood pressure and heart rate of ApoE-KO mice. However, BM-573 had not
effect on blood pressure variability (specifically the very low frequency VLF band (S3 Fig), indi-
cating that BM-573 failed to restore the general alterations of neurohumoral control in
ApoE-KO mice, as described previously [21]. These results indicate that prolonged treatment
with a dual TxAS inhibitor/TP receptor antagonist represents a realistic approach to protect
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the vasculature against endothelial dysfunction and increased blood pressure, both well-estab-
lished risk factors for the development and progression of atherosclerosis.
In conclusion, our study shows that BM-573 prevents and corrects the vasodilatory dysfunc-
tion in resistance arteries at early stage of atherosclerotic lesions by promoting eNOS activity
and reducing oxidative stress. Together with a previous report showing plaque progression pre-
vention by BM-573 in conductance vessels in the same mouse model [14], these data provide
additional rationale to combine antagonism of TP receptors and TxAS inhibition as a thera-
peutic modality to prevent the vascular deleterious consequences of atherogenesis.
Supporting Information
S1 Fig. Contractile response of superior mesenteric arteries isolated from C57BL/6 and
ApoE-KO. (A,D) Contractile response to KCl (50mM) or (B-F) phenylephrine (Phe) (10μM)
in presence or absence of indomethacin (10μM) was measured in resistance mesenteric arteries
from 15-week-old mice treated or not with BM-573 either per os during 8 weeks (10mg/L) or
ex-vivo for 1H (3μM). No significant variations have been recorded in the contraction levels.
Results are expressed as mean ± SEM (N = 5–8 animals in each group).
(TIF)
S2 Fig. Effects of BM-573 on COX-1 expression. Quantitative real-time PCR-based analysis
of COX-1 expression in aortic homogenates from C57BL/6J and ApoE-KO mice treated or not
with BM-573. Results are expressed as mean ± SEM (N = 3–5 animals in each group).
(TIF)
S3 Fig. Effects of BM-573 on blood pressure variability. Effects of long-term BM-573 admin-
istration on blood pressure variability, specifically the very low frequency VLF band, measured
by telemetry in ApoE-KO mice. Values are expressed as mean ± SEM (N = 3–5 animals in each
group).
(TIF)
S1 File. Supplemental Materials and Methods. This complete supplemental information file
contains: (i) Drugs and buffers information; and (ii) methodological details relating to mea-
surements of superoxide anion production by EPR, western blotting, quantitative real-time
PCR and blood pressure and heart rate monitoring.
(DOC)
Acknowledgments
We thank Delphine Demulder and Hrag Esfahani for excellent technical assistance. This
research was supported by ARC and FRSM grants (grant no. ARC 06/11339, FRSM 3.4547.03;
3.4.555.08F). CD and OF are senior research associate and research director (hon) for the
FNRS respectively. Miguel Romero was partially supported by grants from Ministerio de Cien-
cia e Innovación, Instituto de Salud Carlos III, RIC (RD12/0042/0011).
Author Contributions
Conceived and designed the experiments: JMD CD OF. Performed the experiments: MR ELG
IL GR. Analyzed the data: MR ELG IL GR. Contributed reagents/materials/analysis tools: JMD
CD OF. Wrote the paper: MR CD GR.
Effects of BM-573 at Early Stages of Atherosclerosis
PLOS ONE | DOI:10.1371/journal.pone.0152579 March 28, 2016 14 / 17
References
1. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Cir-
culation. 2004; 109: II27–II33. PMID: 15173060
2. Yang Z, Ming XF. Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin
Med Res. 2006; 4: 53–65. PMID: 16595793
3. Alp NJ, McAteer MA, Khoo J, Choudhury RP, Channon KM. Increased endothelial tetrahydrobiopterin
synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunc-
tion and atherosclerosis in ApoE-knockout mice. Arterioscler Thromb Vasc Biol. 2004; 24: 445–450.
PMID: 14707037
4. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacy-
clin formation in patients with atherosclerosis. Circulation. 2000; 102: 840–845. PMID: 10952950
5. Reilly MP, Pratico D, Delanty N, DiMinno G, Tremoli E, Rader D, et al. Increased formation of distinct
F2 isoprostanes in hypercholesterolemia. Circulation. 1998; 98: 2822–2828. PMID: 9860782
6. Feletou M, Vanhoutte PM, Verbeuren TJ. The thromboxane/endoperoxide receptor (TP): the common
villain. J Cardiovasc Pharmacol. 2010; 55: 317–332. PMID: 20422736
7. Zhang M, Song P, Xu J, Zou MH. Activation of NAD(P)H oxidases by thromboxane A2 receptor uncou-
ples endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol. 2011; 31: 125–132. doi: 10.1161/
ATVBAHA.110.207712 PMID: 20947827
8. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor
antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosa-
noids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol. 2000; 20:
1724–1728. PMID: 10894809
9. Dogne JM, Hanson J, Pratico D. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in
atherogenesis. Trends Pharmacol Sci. 2005; 26: 639–644. PMID: 16243403
10. Gendron ME, Thorin E. A change in the redox environment and thromboxane A2 production precede
endothelial dysfunction in mice. Am J Physiol Heart Circ Physiol. 2007; 293: H2508–H2515. PMID:
17644574
11. Lesault PF, Boyer L, Pelle G, Covali-Noroc A, Rideau D, Akakpo S, et al. Daily administration of the TP
receptor antagonist terutroban improved endothelial function in high-cardiovascular-risk patients with
atherosclerosis. Br J Clin Pharmacol. 2011; 71: 844–851. doi: 10.1111/j.1365-2125.2010.03858.x
PMID: 21564160
12. Dogne JM, Hanson J, de Leval X, Kolh P, Tchana-Sato V, de Leval L, et al. Pharmacological characteri-
zation of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel
thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial
thrombosis and its effects on bleeding time. J Pharmacol Exp Ther. 2004; 309: 498–505. PMID:
14742735
13. Ghuysen A, Lambermont B, Dogne JM, Kolh P, Tchana-Sato V, Morimont P, et al. Effect of BM-573 [N-
terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase
inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism. J
Pharmacol Exp Ther. 2004; 310: 964–972. PMID: 15121765
14. Cherdon C, Rolin S, Hanson J, Ooms A, de Leval L, Drion P, et al. BM-573 inhibits the development of
early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane
synthase. Prostaglandins Other Lipid Mediat. 2011; 94: 124–132. doi: 10.1016/j.prostaglandins.2011.
03.001 PMID: 21397034
15. Cyrus T, Yao Y, Ding T, Dogne JM, Pratico D. A novel thromboxane receptor antagonist and synthase
inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient
mice. Eur J Pharmacol. 2007; 561: 105–111. PMID: 17306791
16. Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva I, Frerart F, et al. Endothelial beta3-adrenorecep-
tors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-
generation beta-blocker nebivolol. Circulation. 2005; 112: 1198–1205. PMID: 16116070
17. Desjardins F, Lobysheva I, Pelat M, Gallez B, Feron O, Dessy C, et al. Control of blood pressure vari-
ability in caveolin-1-deficient mice: role of nitric oxide identified in vivo through spectral analysis. Cardio-
vasc Res. 2008; 79: 527–536. doi: 10.1093/cvr/cvn080 PMID: 18349137
18. Romero M, Jimenez R, Sanchez M, Lopez-Sepulveda R, Zarzuelo MJ, O'Valle F, et al. Quercetin inhib-
its vascular superoxide production induced by endothelin-1: Role of NADPH oxidase, uncoupled eNOS
and PKC. Atherosclerosis. 2009; 202: 58–67. doi: 10.1016/j.atherosclerosis.2008.03.007 PMID:
18436224
Effects of BM-573 at Early Stages of Atherosclerosis
PLOS ONE | DOI:10.1371/journal.pone.0152579 March 28, 2016 15 / 17
19. Rouaud F, Romero-Perez M, Wang H, Lobysheva I, Ramassamy B, Henry E, et al. Regulation of
NADPH-dependent Nitric Oxide and reactive oxygen species signalling in endothelial and melanoma
cells by a photoactive NADPH analogue. Oncotarget. 2014; 5: 10650–64. PMID: 25296975
20. Romero M, Jiménez R, Hurtado B, Moreno JM, Rodríguez-Gómez I, López-Sepúlveda R, et al. Lack of
beneficial metabolic effects of quercetin in adult spontaneously hypertensive rats. Eur J Pharmacol.
2010; 627: 242–50. doi: 10.1016/j.ejphar.2009.11.006 PMID: 19903466
21. Pelat M, Dessy C, Massion P, Desager JP, Feron O, Balligand JL. Rosuvastatin decreases caveolin-1
and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/-
mice in vivo. Circulation. 2003; 107: 2480–2486. PMID: 12719275
22. Cui W, Matsuno K, Iwata K, Ibi M, Katsuyama M, Kakehi T, et al. NADPH oxidase isoforms and anti-
hypertensive effects of atorvastatin demonstrated in two animal models. J Pharmacol Sci. 2009; 111:
260–268. PMID: 19881226
23. Jiang F, Guo Y, Salvemini D, Dusting GJ. Superoxide dismutase mimetic M40403 improves endothelial
function in apolipoprotein(E)-deficient mice. Br J Pharmacol. 2003; 139: 1127–1134. PMID: 12871831
24. Kawashima S. Malfunction of vascular control in lifestyle-related diseases: endothelial nitric oxide (NO)
synthase/NO system in atherosclerosis. J Pharmacol Sci. 2004; 96: 411–419. PMID: 15613778
25. Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress.
Arterioscler Thromb Vasc Biol. 2004; 24: 1006–1014. PMID: 15087308
26. Chen X, Zhang H, McAfee S, Zhang C. The reciprocal relationship between adiponectin and LOX-1 in
the regulation of endothelial dysfunction in ApoE knockout mice. Am J Physiol Heart Circ Physiol.
2010; 299: H605–H612. doi: 10.1152/ajpheart.01096.2009 PMID: 20581092
27. Raman KG, Gandley RE, Rohland J, Zenati MS, Tzeng E. Early hypercholesterolemia contributes to
vasomotor dysfunction and injury associated atherogenesis that can be inhibited by nitric oxide. J Vasc
Surg. 2011; 53: 754–763. doi: 10.1016/j.jvs.2010.09.038 PMID: 21163611
28. Beleznai T, Takano H, Hamill C, Yarova P, Douglas G, Channon K, et al. Enhanced K(+)-channel-medi-
ated endothelium-dependent local and conducted dilation of small mesenteric arteries from ApoE(-/-)
mice. Cardiovasc Res. 2011; 92: 199–208. doi: 10.1093/cvr/cvr181 PMID: 21690174
29. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA,et al. Endothelial regulation of
vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydro-
biopterin. Circulation. 2001; 103: 1282–1288. PMID: 11238274
30. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, et al. Impaired vaso-
dilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 1990; 86: 228–
234. PMID: 2195060
31. Belhassen L, Pelle G, Dubois-Rande JL, Adnot S. Improved endothelial function by the thromboxane
A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll
Cardiol.2003; 41: 1198–1204. PMID: 12679222
32. Feletou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (TheWiggers Award Lec-
ture). Am J Physiol Heart Circ Physiol. 2006; 291: H985–1002. PMID: 16632549
33. Gelosa P, Ballerio R, Banfi C, Nobili E, Gianella A, Pignieri A, et al. Terutroban, a thromboxane/prosta-
glandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing sys-
temic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin. J Pharmacol
Exp Ther. 2010; 334: 199–205. doi: 10.1124/jpet.110.165787 PMID: 20332187
34. Drouin A, Farhat N, Bolduc V, Thorin-Trescases N, Gillis MA, Villeneuve L, et al. Up-regulation of
thromboxane A(2) impairs cerebrovascular eNOS function in aging atherosclerotic mice. Pflugers Arch.
2011; 462: 371–383. doi: 10.1007/s00424-011-0973-y PMID: 21617900
35. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF, Vita JA. Ascorbic acid reverses endothelial
vasomotor dysfunction in patients with coronary artery disease. Circulation. 1996; 93: 1107–1113.
PMID: 8653830
36. Qian H, Neplioueva V, Shetty GA, Channon KM, George SE. Nitric oxide synthase gene therapy rapidly
reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of choles-
terol-fed rabbits. Circulation. 1999; 99: 2979–2982. PMID: 10368113
37. Song P, Zhang M,Wang S, Xu J, Choi HC, Zou MH. Thromboxane A2 receptor activates a Rho-associ-
ated kinase/LKB1/PTEN pathway to attenuate endothelium insulin signaling. J Biol Chem. 2009; 284:
17120–17128. doi: 10.1074/jbc.M109.012583 PMID: 19403525
38. Liu CQ, Leung FP, Wong SL, WongWT, Lau CW, Lu L, et al. Thromboxane prostanoid receptor activa-
tion impairs endothelial nitric oxide-dependent vasorelaxations: the role of Rho kinase. Biochem Phar-
macol. 2009; 78: 374–381. doi: 10.1016/j.bcp.2009.04.022 PMID: 19409373
Effects of BM-573 at Early Stages of Atherosclerosis
PLOS ONE | DOI:10.1371/journal.pone.0152579 March 28, 2016 16 / 17
39. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ET, et al. p47phox is required
for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest. 2001; 108: 1513–1522. PMID:
11714743
40. Terashima M, Ohashi Y, Azumi H, Otsui K, Kaneda H, Awano K, et al. Impact of NAD(P)H oxidase-
derived reactive oxygen species on coronary arterial remodeling: a comparative intravascular ultra-
sound and histochemical analysis of atherosclerotic lesions. Circ Cardiovasc Interv. 2009; 2: 196–204.
doi: 10.1161/CIRCINTERVENTIONS.108.799502 PMID: 20031716
41. Feletou M, Huang Y, Vanhoutte PM. Endothelium-mediated control of vascular tone: COX-1 and COX-
2 products. Br J Pharmacol.2001; 164: 894–912.
42. Linton MF, Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis. Curr Opin Pharmacol.
2004; 4: 116–123. PMID: 15063354
43. WongWT, Tian XY, Huang Y. Endothelial dysfunction in diabetes and hypertension: cross talk in RAS,
BMP4, and ROS-dependent COX-2-derived prostanoids. J Cardiovasc Pharmacol. 2013; 61: 204–
214. doi: 10.1097/FJC.0b013e31827fe46e PMID: 23232839
44. Delannoy E, Courtois A, Freund-Michel V, Leblais V, Marthan R, Muller B. Hypoxia-induced hyperreac-
tivity of pulmonary arteries: role of cyclooxygenase-2, isoprostanes, and thromboxane receptors. Cardi-
ovasc Res. 2010; 85: 582–592. doi: 10.1093/cvr/cvp292 PMID: 19710084
45. Petri MH, Tellier C, Michiels C, Ellertsen I, Dogné JM, Bäck M. Effects of the dual TP receptor antago-
nist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle
cells. Biochem Biophys Res Commun. 2013; 441: 393–398. doi: 10.1016/j.bbrc.2013.10.078 PMID:
24161392
46. Arruda RM, Peotta VA, Meyrelles SS, Vasquez EC. Evaluation of vascular function in apolipoprotein E
knockout mice with angiotensin-dependent renovascular hypertension. Hypertension. 2005; 46: 932–
936. PMID: 16087779
47. Martinez-Miguel P, Raoch V, Zaragoza C, Valdivielso JM, Rodriguez-Puyol M, Rodriguez-Puyol D,
et al. Endothelin-converting enzyme-1 increases in atherosclerotic mice: potential role of oxidized low
density lipoproteins. J Lipid Res. 2009; 50: 364–375. doi: 10.1194/jlr.M800215-JLR200 PMID:
18997155
Effects of BM-573 at Early Stages of Atherosclerosis
PLOS ONE | DOI:10.1371/journal.pone.0152579 March 28, 2016 17 / 17
